Rury R Holman

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
    Rury R Holman
    Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom Electronic address
    Am Heart J 168:23-9.e2. 2014
  2. ncbi request reprint Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, University of Oxford, Oxford, UK Electronic address
    Lancet 383:2008-17. 2014
  3. doi request reprint Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
    Rury R Holman
    Diabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, UK
    Nat Rev Endocrinol 9:67-8. 2013
  4. pmc Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
    Julia Lawton
    Centre for Population Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK
    Trials 12:108. 2011
  5. ncbi request reprint Three-year efficacy of complex insulin regimens in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    N Engl J Med 361:1736-47. 2009
  6. doi request reprint Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
    R R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, UK
    Diabetologia 52:50-9. 2009
  7. doi request reprint 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
  8. doi request reprint Long-term follow-up after tight control of blood pressure in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1565-76. 2008
  9. ncbi request reprint Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, University of Oxford, Headington, Oxford, United Kingdom
    N Engl J Med 357:1716-30. 2007
  10. ncbi request reprint Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74
    Ravi Retnakaran
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes 55:1832-9. 2006

Detail Information

Publications45

  1. ncbi request reprint Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
    Rury R Holman
    Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom Electronic address
    Am Heart J 168:23-9.e2. 2014
    ..Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease...
  2. ncbi request reprint Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, University of Oxford, Oxford, UK Electronic address
    Lancet 383:2008-17. 2014
    ....
  3. doi request reprint Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
    Rury R Holman
    Diabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, UK
    Nat Rev Endocrinol 9:67-8. 2013
    ..Studies in 2012 have re-affirmed the safety of early insulin treatment, metformin use in renal impairment, and shown β-cell function preservation over several years...
  4. pmc Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
    Julia Lawton
    Centre for Population Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK
    Trials 12:108. 2011
    ..5%) among patients who participated in the Treating to Target in Type 2 Diabetes Trial (4-T). The objective was to inform interpretation of trial outcomes and provide recommendations for future trial delivery...
  5. ncbi request reprint Three-year efficacy of complex insulin regimens in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    N Engl J Med 361:1736-47. 2009
    ..Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited...
  6. doi request reprint Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
    R R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, UK
    Diabetologia 52:50-9. 2009
    ....
  7. doi request reprint 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
    ..We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes...
  8. doi request reprint Long-term follow-up after tight control of blood pressure in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1565-76. 2008
    ....
  9. ncbi request reprint Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, University of Oxford, Headington, Oxford, United Kingdom
    N Engl J Med 357:1716-30. 2007
    ..Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited...
  10. ncbi request reprint Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74
    Ravi Retnakaran
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes 55:1832-9. 2006
    ..Distinct sets of risk factors are associated with the development of these two outcomes, consistent with the concept that they are not linked inexorably in type 2 diabetes...
  11. ncbi request reprint Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66
    Richard J Stevens
    Diabetes Trials Unit and the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U K
    Diabetes Care 27:201-7. 2004
    ..We investigated whether the risk of MI or stroke being fatal in type 2 diabetes can be estimated using information available around the time diabetes is diagnosed...
  12. ncbi request reprint Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
    Rury R Holman
    Diabetes Trials Unit, OCDEM, University of Oxford, Oxford OX3 7LJ, UK
    Metabolism 55:S2-5. 2006
    ....
  13. ncbi request reprint Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)
    Amanda I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, and South Cleveland Hospital, Cleveland, United Kingdom
    Kidney Int 63:225-32. 2003
    ..This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal replacement therapy (RRT), and death...
  14. ncbi request reprint Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69
    David R Matthews
    Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, England
    Arch Ophthalmol 122:1631-40. 2004
    ..To determine the relationship between tight blood pressure (BP) control and the different aspects of diabetic retinopathy in patients with type 2 diabetes mellitus (DM)...
  15. ncbi request reprint A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
    M Angelyn Bethel
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United Kingdom
    Am J Cardiol 112:231-7. 2013
    ..In conclusion, our novel risk classification paradigm based on potential treatment could be used to guide clinical practice based on cost and availability of screening tests. ..
  16. ncbi request reprint Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes
    Ruth L Coleman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford, UK
    Diabetes Care 30:1292-3. 2007
  17. ncbi request reprint Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
    Diabetes Care 28:1796-7. 2005
  18. ncbi request reprint Perceptions of heart attack risk amongst individuals with diabetes
    Hermione C Price
    Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, United Kingdom
    Prim Care Diabetes 3:239-44. 2009
    ..We undertook a qualitative study to investigate lay perceptions of heart attack risk amongst individuals with diabetes in order to gather information about underlying perceptions concerning risk and risk reduction strategies...
  19. ncbi request reprint Life expectancy in individuals with type 2 diabetes: implications for annuities
    Hermione C Price
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and MetabolismUniversity of Oxford, Oxford, UK
    Med Decis Making 30:409-14. 2010
    ..Insurance companies often offer people with diabetes ''enhanced impaired life annuity'' at preferential rates, in view of their reduced life expectancy...
  20. ncbi request reprint Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78
    Carole A Cull
    Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford, United Kingdom, OX3 7LJ
    Circulation 116:2119-26. 2007
    ..We examined retrospectively the degree to which the presence of MetS in individuals with type 2 diabetes mellitus increased their risk of diabetic complications using United Kingdom Prospective Diabetes Study data...
  21. ncbi request reprint Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes
    Hermione C Price
    Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Headington, UK
    Fam Pract 26:351-8. 2009
    ..People need to perceive a risk in order to build an intention-to-change behaviour yet our ability to interpret information about risk is highly variable...
  22. ncbi request reprint UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes
    Richard J Stevens
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    J Diabetes Complications 16:371-6. 2002
    ..We conclude that duration of diabetes and HbA(1c) level better predict risk for photocoagulation when treated as two components of cumulative glucose exposure, than when treated as independent risk factors...
  23. pmc Evaluation of a self-administered oral glucose tolerance test
    M Angelyn Bethel
    Diabetes Trials Unit Translational Research Group, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United Kingdom
    Diabetes Care 36:1483-8. 2013
    ..To assess the feasibility of using a disposable, self-administered, capillary blood sampling oral glucose tolerance test (OGTT) device in a community setting...
  24. ncbi request reprint Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
    Janine Hartweg
    Division of Public Health and Primary Healthcare, University of Oxford, Oxford, UK
    Curr Opin Lipidol 20:30-8. 2009
    ....
  25. ncbi request reprint Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
    Hermione C Price
    University of Oxford Diabetes Trials Unit, Oxford, UK
    Nat Clin Pract Cardiovasc Med 6:168-9. 2009
    ..This paradox is unhelpful and the guidelines should be relaxed until definitive evidence becomes available...
  26. ncbi request reprint Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61
    Stephen Colagiuri
    Diabetes Center, Prince of Wales Hospital, Randwick, Australia Diabetes Trials Unit, Oxford Center for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes Care 25:1410-7. 2002
    ..Earlier detection and treatment may reduce this burden, but evidence to support this approach is lacking...
  27. ncbi request reprint The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults
    Minal Desai
    Diabetes Research Laboratories, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes 55:1890-4. 2006
    ..In conclusion, differences in VNTR-encoded susceptibility do not explain the differences in clinical presentation that distinguish classical type 1 diabetes and LADA...
  28. ncbi request reprint Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36
    Philip M Clarke
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
    Diabetes Care 29:1506-11. 2006
    ..We sought to ascertain quality-of-life measures and utility values associated with visual acuity in type 2 diabetes...
  29. ncbi request reprint A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test
    Nina Mohanlal
    Churchill Hospital, Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism OCEM, Headington, U K
    Diabetes Care 27:89-94. 2004
    ..A standardized method of assessing postprandial triglyceride changes is not available. We evaluated an oral triglyceride tolerance test (OTTT) designed for routine clinical and research use...
  30. pmc Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data
    Jose Leal
    Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, UK
    Diabetes Care 36:1541-6. 2013
    ..To evaluate the accuracy of the UK Prospective Diabetes Study Outcomes Model (UKPDS-OM) in predicting clinical outcomes during the UKPDS posttrial monitoring (PTM) period...
  31. pmc The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial
    Hermione C Price
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LJ, UK
    Cardiovasc Diabetol 7:21. 2008
    ..This study has been designed to determine if personalised CVD risk appreciation can increase physical activity in adults at high risk of CVD...
  32. ncbi request reprint UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes
    Amanda I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    Diabetes Care 25:894-9. 2002
    ..To determine the role of hyperglycemia in prospective analyses of peripheral vascular disease (PVD) in type 2 diabetes, taking into account other potential risk factors...
  33. ncbi request reprint Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
    Robert M Califf
    Duke Transitional Medicine Institute, Durham, NC 27715, USA
    Am Heart J 156:623-32. 2008
    ..The study was designed to evaluate whether reducing postprandial hyperglycemia, blockade of the renin-angiotensin-aldosterone system, or both interventions reduce the risk of T2DM or cardiovascular events in patients with IGT...
  34. ncbi request reprint Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73
    Alex D Wright
    University Hospital, Birmingham, UK
    J Diabetes Complications 20:395-401. 2006
    ....
  35. ncbi request reprint A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
    Giancarlo Viberti
    Guy s, King s, and St Thomas School of Medicine, King s College, London, U K
    Diabetes Care 25:1737-43. 2002
    ....
  36. ncbi request reprint Effect of ramipril on the incidence of diabetes
    Jackie Bosch
    McMaster University, Hamilton, Canada
    N Engl J Med 355:1551-62. 2006
    ..Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension...
  37. doi request reprint Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Stud
    David M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Diabetes Care 31:173-5. 2008
  38. ncbi request reprint Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
    Michael N Cook
    Department of Epidemiology, Merck Research Laboratories, Merck, BL 1 7, P O Box 4, West Point, PA 19486 0004, USA
    Diabetes Care 28:995-1000. 2005
    ..To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF)...
  39. ncbi request reprint Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
    Alex Wright
    University Hospital, Birmingham, U K
    Diabetes Care 25:330-6. 2002
    ..To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is inadequate in individuals with type 2 diabetes...
  40. ncbi request reprint Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT)
    Steven E Kahn
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington 98108, USA
    Diabetes Care 31:845-51. 2008
    ..The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT)...
  41. ncbi request reprint Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
    Steven E Kahn
    Department of Internal Medicine, Division of Metbolism, Endocrinology and Nurtrition, VA Puget Sound Health Care System, 151, 1660 S Columbian Way, Seattle, WA 98108, USA
    Diabetes 55:2357-64. 2006
    ..Further, for CRP and fibrinogen this relationship is determined by body adiposity and not by insulin sensitivity or glucose control...
  42. ncbi request reprint Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
    Christoph Stettler
    Department of Social and Preventive Medicine, University of Bern, Switzerland
    Am Heart J 152:27-38. 2006
    ..Uncertainty persists concerning the effect of improved long-term glycemic control on macrovascular disease in diabetes mellitus (DM)...
  43. ncbi request reprint Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    Steven E Kahn
    Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle 98108, USA
    N Engl J Med 355:2427-43. 2006
    ..The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known...
  44. ncbi request reprint Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    David M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, 02114, USA
    Diabetes Care 29:1963-72. 2006
  45. ncbi request reprint A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al
    Timothy M E Davis
    Diabetes Care 29:2560; author reply 2560-1. 2006